Charles Schwab Investment Management Inc. Raises Stock Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Charles Schwab Investment Management Inc. boosted its position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRXFree Report) by 9.1% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,594,436 shares of the biotechnology company’s stock after purchasing an additional 133,629 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.78% of BioCryst Pharmaceuticals worth $9,551,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of BCRX. JGP Global Gestao de Recursos Ltda. acquired a new stake in shares of BioCryst Pharmaceuticals in the 4th quarter worth $64,000. MA Private Wealth purchased a new position in shares of BioCryst Pharmaceuticals during the 4th quarter valued at about $76,000. Great Valley Advisor Group Inc. raised its stake in shares of BioCryst Pharmaceuticals by 34.7% during the 3rd quarter. Great Valley Advisor Group Inc. now owns 16,300 shares of the biotechnology company’s stock valued at $115,000 after buying an additional 4,200 shares during the last quarter. Mackenzie Financial Corp raised its stake in shares of BioCryst Pharmaceuticals by 74.7% during the 4th quarter. Mackenzie Financial Corp now owns 23,439 shares of the biotechnology company’s stock valued at $140,000 after buying an additional 10,026 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its stake in shares of BioCryst Pharmaceuticals by 387.0% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 23,692 shares of the biotechnology company’s stock valued at $142,000 after buying an additional 18,827 shares during the last quarter. 85.88% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at BioCryst Pharmaceuticals

In other news, Director Nancy J. Hutson acquired 5,000 shares of BioCryst Pharmaceuticals stock in a transaction that occurred on Monday, May 20th. The stock was purchased at an average price of $6.38 per share, for a total transaction of $31,900.00. Following the completion of the transaction, the director now directly owns 86,818 shares in the company, valued at $553,898.84. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other BioCryst Pharmaceuticals news, insider Helen M. Thackray purchased 30,000 shares of the business’s stock in a transaction on Tuesday, May 14th. The stock was bought at an average cost of $5.86 per share, for a total transaction of $175,800.00. Following the acquisition, the insider now owns 272,139 shares of the company’s stock, valued at approximately $1,594,734.54. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Nancy J. Hutson purchased 5,000 shares of the business’s stock in a transaction on Monday, May 20th. The stock was acquired at an average price of $6.38 per share, with a total value of $31,900.00. Following the completion of the acquisition, the director now directly owns 86,818 shares in the company, valued at approximately $553,898.84. The disclosure for this purchase can be found here. Insiders bought a total of 95,740 shares of company stock worth $546,342 over the last 90 days. Company insiders own 4.80% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on BCRX. HC Wainwright restated a “buy” rating and issued a $30.00 price target on shares of BioCryst Pharmaceuticals in a research note on Tuesday, May 7th. JMP Securities lifted their price target on BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a “market outperform” rating in a research note on Tuesday, May 7th. Finally, Needham & Company LLC restated a “buy” rating and issued a $12.00 price target on shares of BioCryst Pharmaceuticals in a research note on Tuesday, May 7th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $14.00.

Check Out Our Latest Analysis on BioCryst Pharmaceuticals

BioCryst Pharmaceuticals Price Performance

NASDAQ:BCRX opened at $6.57 on Friday. The firm has a market capitalization of $1.36 billion, a PE ratio of -6.14 and a beta of 1.96. The business’s fifty day moving average price is $5.12 and its 200 day moving average price is $5.50. BioCryst Pharmaceuticals, Inc. has a 12 month low of $4.03 and a 12 month high of $8.96.

BioCryst Pharmaceuticals (NASDAQ:BCRXGet Free Report) last released its quarterly earnings data on Monday, May 6th. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.06. The company had revenue of $92.80 million during the quarter, compared to analyst estimates of $85.62 million. During the same quarter in the prior year, the company earned ($0.28) EPS. The business’s revenue was up 34.9% on a year-over-year basis. As a group, equities analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.66 EPS for the current year.

BioCryst Pharmaceuticals Profile

(Free Report)

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.

Read More

Institutional Ownership by Quarter for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.